168 results on '"Kan, Hiromi"'
Search Results
2. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing
3. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice
4. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A
5. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy
6. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients
7. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease
8. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection
9. Emergence of drug resistance‐associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir‐treated chronic hepatitis C patients
10. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma
11. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C
12. A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion
13. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study
14. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus
15. Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma
16. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy
17. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report
18. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis
19. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
20. Eicosapentaenoic acid/arachidonic acid ratio as a possible link between non-alcoholic fatty liver disease and cardiovascular disease
21. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers
22. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease
23. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C
24. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib
25. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients
26. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration
27. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy
28. B-flow ultrasound imaging of intraplaque blood flow in patients with carotid artery stenosis
29. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure
30. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice
31. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
32. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus
33. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology
34. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus
35. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients
36. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease
37. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report
38. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones
39. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
40. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus
41. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay
42. Combination Therapies with Daclatasvir and Asunaprevir on NS3-D168 Mutated HCV in Human Hepatocyte Chimeric Mice
43. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C.
44. Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma
45. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report
46. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis
47. Role of 3‐D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
48. Eicosapentaenoic acid/arachidonic acid ratio as a possible link between non-alcoholic fatty liver disease and cardiovascular disease
49. Hepatitis B infection derived from a donor and de novo autoimmune hepatitis subsequent to pegylated-interferon treatment for recurrent hepatitis C after living-liver transplantation: A case report
50. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.